Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy

NCT07039656 | Recruiting Phase 2

• 1 other identifier: KY2024-1057-03
• Study Type: interventional
• Target: 211
• Locations: 1 country
• Sites: 1

Brief Summary

This is a two-cohort, multicenter, Phase II study to evaluate the efficacy and safety of 3-4 cycles of toripalimab (JS001) plus chemotherapy followed by toripalimab maintenance treatment up to one year in participants with completely resected non-small cell lung cancer (NSCLC) stratified by prior neoadjuvant treatment status, as measured by disease-free survival (DFS) and overall survival (OS). Researchers will compare outcomes between two cohorts:

1. 1.Cohort 1: Stage IB-IIIB participants following completely resection without neoadjuvant therapy;
2. 2.Cohort 2: Stage IIB-III participants with non-MPR or MPR but lymph node positivity after neoadjuvant therapy.

Conditions

Stage IB-IIIB NSCLC; Stage IIB-III NSCLC

Keywords

Toripalimab; MRD; Adjuvant therapy

Outcome Measures

Primary Outcomes (1)

• 2-year Disease-Free Survival

  DFS was defined as the time from the start of the treatment to either the date of disease recurrence or death (whatever the cause) as assessed by the investigator. Recurrence of disease was defined as local regional recurrence, a distant (metastatic) recurrence, or a second primary cancer. Occurrence of a second extra-pulmonary malignancy was considered to be an event.

  24 months

Secondary Outcomes (2)

• Overall Survival

  60 months

• Adverse events

  24 months

Study Arms (2)

Stage IB-IIIB participants following completely resection without neoadjuvant therapy

EXPERIMENTAL

Drug: Toripalimab; Drug: Cisplatin-based chemotherapy

Stage IIB-III participants with non-MPR or MPR but lymph node positivity after neoadjuvant therapy

EXPERIMENTAL

Drug: Toripalimab; Drug: Cisplatin-based chemotherapy

Interventions

Toripalimab DRUG

Participants will receive Toripalimab (240 mg IV) Q3W for 17 cycles (cycle length=21 days).

Stage IB-IIIB participants following completely resection without neoadjuvant therapy; Stage IIB-III participants with non-MPR or MPR but lymph node positivity after neoadjuvant therapy

Cisplatin-based chemotherapy DRUG

Cisplatin\[75 mg/m\^2 IV Q3W\]/carboplatin\[AUC 5 IV Q3W\]+paclitaxel\[260 mg/m\^2 IV Q3W\] or cisplatin\[75 mg/m\^2 IV Q3W)\]/carboplatin\[AUC 5 IV Q3W\]+ pemetrexed\[500 mg/m2 IV Q3W\],dependent on tumor histology. Participants will receive Chemotherapy for 3-4 cycles

Stage IB-IIIB participants following completely resection without neoadjuvant therapy; Stage IIB-III participants with non-MPR or MPR but lymph node positivity after neoadjuvant therapy

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed Informed Consent Form
• Patient with age ≥ 18 and ≤75 years old, gender is not limited.
• Cohort 1: Histological diagnosis of Stage IB -IIIB NSCLC without anti-cancer treatment; Cohort 2: Histological diagnosis of Stage IIB-III NSCLC with non-MPR or MPR but lymph node positivity after neoadjuvant chemoimmunotherapy; (per American Joint Committee on Cancer staging system (AJCC) staging system, 8th edition)
• Participants must have had complete resection of NSCLC 60 days
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
• Adequate organ function performed within 10 days of treatment initiation
• Male or female patients of childbearing potential will voluntarily use an effective method of contraception, e.g., double-barrier contraception, condoms, oral or injectable contraceptives, IUDs, etc., during the study period and for the last 6 months of study drug use. All female patients will be considered of childbearing potential unless the female patient is naturally menopausal, artificially menopausal or sterilised (e.g. hysterectomy, bilateral adnexectomy or radiation ovarian irradiation).

You may not qualify if:

• Pathological histology confirmed the diagnosis of small cell lung cancer pathological type;
• Treatment with prior systemic chemotherapy at any time
• Confirmed EGFR or ALK mutations
• Patient has a history of active autoimmune disease or autoimmune disease that may recur
• Active hepatitis B and C patients will need to be on relevant antiviral therapy, have HBV-DNA \<2000 IU/ml (\<104 copies/ml) and have received anti-HBV therapy for at least 14 days prior to study participation, and continue therapy for the duration of the treatment period; HCV RNA-positive patients must be on antiviral therapy and have a liver function that is within the elevated CTCAE grade 1;
• Known allergy to chemotherapy drugs including cisplatin, paclitaxel, albumin-paclitaxel and pemetrexed;
• History of allergy to monoclonal antibody drugs
• Patients with previous allogeneic stem cell or parenchymal organ transplantation
• Having a mental illness or any other condition that renders treatment non-compliant
• Patients unable or unwilling to sign the informed consent form
• The investigator considered that the patient's condition may affect compliance with the protocol or make participation in this study unsuitable.

Sponsors & Collaborators

• Wen-zhao ZHONG: lead
• Shanghai Junshi Bioscience Co., Ltd.: collaborator

Study Sites (1)

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, 510080, China

RECRUITING

MeSH Terms

Interventions

toripalimab

Central Study Contacts

Wen-Zhao Zhong, MD

CONTACT

86-13609777314; 13609777314@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Head of Thoracic Surgery

Study Record Dates

• First Submitted: June 18, 2025
• First Posted: June 26, 2025
• Study Start: January 1, 2025
• Primary Completion (Estimated): December 30, 2028
• Study Completion (Estimated): December 31, 2030
• Last Updated: August 7, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)